Comparison of Flutiform
- Conditions
- Diseases of th respiratory system
- Registration Number
- KCT0003540
- Lead Sponsor
- Gachon University Gil Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
1. Age: 19 years or older
2. Typical symptom of asthma: dyspnea and wheezing which is aggravated at night and dawn, or by upper respiratory infection, exercise, climate change, air pollution, allergen exposure, stimulatory odor.
3. Reversible airway obstruction (FEV1 increase by 12% and 200ml after salbutamol inhalation or other asthma treatment) or airway hyperresponsiveness (PC20 16mg/mL or less in methacholine challenge test)
4. The use of inhaled coticosteroid and long-acting beta2 agonist is recommended according to the gulideline of Global Initiative of Asthma (GINA) (Step3)
5. Subjects who can use pressurized metered dose inhaler (pMDI).
1. Malignancy or other severe diseases which can influence on this study
2. Patients who previously used Flutiform® or Foster®.
3. Pregnancy or lactation (for female subjects)
4. Flutiform® and Foster® are not appropriate to use for other reason
5. Subjects who do not want or reject to participate in this study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of Life Questionnaire for Adult Korean Asthmatics (Severity and frequency of symptoms, Activity limitation, Patients' stress and concern about asthma and asthma exacerbation
- Secondary Outcome Measures
Name Time Method Asthma Control Questionnaire (Day symptom, Night symptom, Reliever use, Activity limitation, Forced expiratory volume in 1 second on spirometry);Asthma Control Test (Day symptom, Night symptom, Reliever use, Activity limitation, Overall asthma control);Forced expiratory volume in 1 second in pulmonary function test;Skill in handling inhaler;Compliance to inhaler;Preference of inhaler